Alla studier
RekryteringTerapeutisk bekräftande (Fas III)Interventionell

An open-label, single-arm, multicenter study to evaluate the efficacy and safety of caplacizumab and immunosuppressive therapy without first-line therapeutic plasma exchange in adults with immunemediated thrombotic thrombocytopenic purpura

This study is investigating a new approach to treating a rare and serious blood condition called immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP). Currently, a common treatment for iTTP is therapeutic plasma exchange (TPE), which involves filtering the patient's blood. This study aims to see if a medication called Cablivi, when given alongside standard immune-suppressing treatments, can help adult patients with iTTP go into remission and recover without needing TPE. Researchers will be closely monitoring how well patients respond to the treatment and if there are any side effects. This is a Phase III study, meaning it's a later stage of research designed to confirm if the new treatment is effective and safe.

Överblick

Status
Rekrytering
Fas
Terapeutisk bekräftande (Fas III)
Sponsor
Sanofi-Aventis Forskning & Utveckling
Inskrivningsmål
44
Starta
11 jul 2024

Vad handlar denna studie om?

This study is about finding a new way to treat a rare but serious blood disease called immune-mediated Thrombotic Thrombocytopenic Purpura, or iTTP for short. In iTTP, your body mistakenly attacks itself, leading to tiny blood clots forming in small blood vessels. This can cause problems with your blood, kidneys, brain, and heart.

Currently, a common treatment for iTTP is called therapeutic plasma exchange, often shortened to TPE. This is a procedure where a machine filters your blood to remove harmful substances. While TPE is effective, it can be quite intensive and involves frequent hospital visits. This study is exploring if a new medicine called Cablivi, given along with other medicines that calm down your immune system, can help adult patients with iTTP get better and go into remission without needing the TPE procedure.

The main goal of the study is to see how many patients get better and into remission without needing TPE. The researchers will also be carefully watching for any side effects and how quickly people respond to the new treatment. This is an important step in potentially offering patients with iTTP a different, possibly less intensive, treatment option in the future.

Viktiga punkter

  • Tests a new medicine (Cablivi) for iTTP.
  • Aims to help patients get better without plasma exchange.
  • Combines Cablivi with other immune-suppressing treatments.
  • Involves regular hospital visits and monitoring.
  • Open to adults 18 years and older with iTTP.
  • Du kan sluta delta när som helst.

Vem kan vara berättigad?

To join this study, you must be an adult, 18 years or older, and have been diagnosed with immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP).

The study is open to both men and women with iTTP. There will be other specific medical checks to make sure the treatment is safe for you and that the study results are clear. These will involve looking at your overall health and any other medications you might be taking.

Kan denna studie passa dig?

Svara på dessa snabba frågor för att se om du kan vara berättigad. Detta är endast en vägledning — forskarteamet fattar det slutgiltiga beslutet.

  1. Är du 18 år eller äldre?
  2. Have you been diagnosed with immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)?
  3. Are you able to attend regular hospital appointments for check-ups and treatment?
  4. Are you generally well enough to participate in a medical study in addition to your iTTP diagnosis?
Svara på varje fråga för att se ditt resultat.

Vad innebär deltagande?

If you decide to take part in this study, you would receive the study medication, Cablivi, as an injection, along with other treatments to suppress your immune system. You would have regular appointments at the hospital or clinic for check-ups, blood tests, and to make sure the treatment is working well and safely. The study would involve close monitoring, especially in the beginning. The main part of the treatment will last for about 84 days (around 12 weeks), but you would be followed up for a longer period, up to 168 days (about 24 weeks), to see how you are doing after treatment.

Potentiella risker och fördelar

Participating in this study might offer the benefit of receiving a new treatment that could help you recover from iTTP without needing plasma exchange, potentially making your treatment journey less intensive. However, like all medicines, Cablivi can have side effects, and some might be serious. The study team will carefully monitor you for any problems. You are always in control of your decision; you can choose to join, and you can stop participating at any time, for any reason, without it affecting your usual medical care.

Platser (9)

Vissa platsangivelser är ungefärliga. Vi arbetar på att förbättra detta — vänligen kontrollera med testteamet innan du reser.
  • —
    Obekräftad
    Nederländerna
  • —
    Obekräftad
    Tjeckien
  • —
    Obekräftad
    Spanien
  • —
    Obekräftad
    Österrike
  • —
    Obekräftad
    Italien
  • —
    Obekräftad
    Tyskland
  • —
    Obekräftad
    Frankrike
  • —
    Obekräftad
    Belgien
  • —
    Obekräftad
    Grekland

Vanliga frågor

What is iTTP?

iTTP is a rare blood disorder where your immune system mistakenly attacks healthy cells, causing tiny blood clots to form and leading to problems with your blood and organs.

What is plasma exchange?

Plasma exchange is a procedure that cleans your blood by removing harmful substances, often used to treat iTTP. This study is looking at ways to avoid needing it.

What is Cablivi?

Cablivi is a medicine being tested in this study. It's given as an injection and aims to stop the blood clots from forming in iTTP.

Will I still get other treatments if I join?

Yes, you would receive Cablivi along with other standard treatments that help calm your immune system.

How long will this study last for me?

The main treatment phase will be about 12 weeks, followed by a monitoring period, making the total study time up to 24 weeks.

Hur du får reda på mer

Prata alltid med din läkare eller specialist innan du bestämmer dig för att delta i en studie.

Intresserad av att delta?

Registrera ditt intresse

Dela dina uppgifter och forskarteamet för "An open-label, single-arm, multicenter study to evaluate the…" kommer att kontakta dig om du kan vara berättigad. Prata alltid med din läkare innan du går med på att delta.

Diskussion

Gemenskapsdiskussion

Drivs av vårt forum på community.patient.info. Var vänlig och respektfull — detta är inte medicinsk rådgivning.